Data as of Mar 14
| +0.02 / +0.94%|
Soligenix, Inc. is a clinical stage biopharmaceutical company. It is focused on developing products to treat serious gastrointestinal diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics. The company operates through BioTherapeutics and Vaccines/BioDefense segments. The BioTherapeutics business segment intends to develop oral beclomethasone dipropionate indications such as pediatric crohn's disease and acute radiation enteritis. The Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine, and VeloThrax, its anthrax vaccine, and OrbeShield, its gastrointestinal acute radiation syndrome therapeutic. Soligenix was founded in 1987 and is headquartered Princeton, NJ.
|Christopher J. Schaber||Chairman, President & Chief Executive Officer|
|Joseph Michael Warusz||Chief Financial Officer, Secretary & VP|
|Robert N. Brey||Chief Scientific Officer & Senior Vice President|
|Oreola Donini||Vice President-Preclinical Research & Development|
|Richard C. Straube||Chief Medical Officer & Senior Vice President|